Objectives: To determine the safety, tolerability, pharmacokinetics, and immunomodulatory effects of a 6-week course of atorvastatin in patients with acute Kawasaki disease with coronary artery (CA) aneurysm (CAA).
Study Design: This was a Phase I/IIa 2-center dose-escalation study of atorvastatin (0.125-0.